Literature DB >> 9439541

The effect of norepinephrine on insulin secretion and glucose effectiveness in non-insulin-dependent diabetes.

J M Walters1, G M Ward, J Barton, R Arackal, R C Boston, J D Best, F P Alford.   

Abstract

It has previously been shown that in normal subjects, physiological elevation of norepinephrine (NE) impairs insulin sensitivity (Si) but does not influence insulin secretion. The aim of this study was to determine the effect of short-term physiological elevation of NE on insulin secretion, Si, and glucose-mediated glucose disposal, or the glucose effectiveness index (Sg), in non-insulin-dependent diabetes mellitus (NIDDM). Two intravenous glucose tolerance tests (IVGTTs) were performed in eight well-controlled NIDDM patients, using a supplemental exogenous insulin infusion to achieve an approximation of normal endogenous insulin secretion. The IVGTTs were performed in random order after 30 minutes of either the saline (SAL) or NE (25 ng/kg/min) infusions, which were continued throughout the 3-hour IVGTT. Sg and Si were estimated by minimal model analysis of the IVGTT data as previously described. Plasma C-peptide was used to estimate insulin secretion rate using the ISEC program. NE infusion produced approximately a threefold increase in plasma NE, associated with (1) a significant reduction in glucose disposal ([KG] SAL v NE, 0.73 +/- 0.06 v 0.61 +/- 0.06 x 10(-2).min-1, P < .05), (2) no reduction in Si (2.33 +/- 0.8 v 2.62 +/- 0.9 x 10(-4).min-1/mU/L, NS), (3) a reduced mean second-phase insulin secretion rate (1.21 +/- 0.19 v 1.01 +/- 0.16 x 10(-3) pmol/kg/min per mmol/L glucose, P < .05), (4) a significant increase in Sg (0.89 +/- 0.08 v 1.63 +/- 0.2 x 10(-2).min-1, P < .05), and (5) a corresponding increase in glucose effectiveness at zero insulin ([GEZI] 0.55 +/- 0.13 v 1.30 +/- 0.33 x 10(-2).min-1, P < .05). These results show that in contrast to normal subjects, physiological elevation of NE in NIDDM does not result in a reduction in Si, but causes a reduction in glucose disposal related to inhibition of insulin secretion that is only partially compensated for by increased Sg.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9439541     DOI: 10.1016/s0026-0495(97)90146-3

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  6 in total

1.  Antidepressant continuation in pregnancy and risk of gestational diabetes.

Authors:  Paige D Wartko; Noel S Weiss; Daniel A Enquobahrie; K C Gary Chan; Alyssa Stephenson-Famy; Beth A Mueller; Sascha Dublin
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-07-12       Impact factor: 2.890

Review 2.  Potential Therapeutic Targeting Neurotransmitter Receptors in Diabetes.

Authors:  Xiaohui Pan; Shibing Tao; Nanwei Tong
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-20       Impact factor: 6.055

3.  Effects of pharmacological doses of 2-deoxyglucose on plasma catecholamines and glucose levels in patients with schizophrenia.

Authors:  Igor Elman; David Rott; Alan I Green; Daniel D Langleben; Scott E Lukas; David S Goldstein; Alan Breier
Journal:  Psychopharmacology (Berl)       Date:  2004-06-04       Impact factor: 4.530

4.  Diabetes hospitalizations and deaths in a cohort of treatment-seeking illicit drug users.

Authors:  Alex Aregbesola; Ifeoma N Onyeka; Olubunmi Olubamwo; Kimmo Ronkainen; Jari Tiihonen; Jaana Föhr; Jussi Kauhanen
Journal:  SAGE Open Med       Date:  2018-05-01

Review 5.  The Effects of Mental Stress on Non-insulin-dependent Diabetes: Determining the Relationship Between Catecholamine and Adrenergic Signals from Stress, Anxiety, and Depression on the Physiological Changes in the Pancreatic Hormone Secretion.

Authors:  Hilda Wong; Jaya Singh; Ryan M Go; Nancy Ahluwalia; Michelle A Guerrero-Go
Journal:  Cureus       Date:  2019-08-24

6.  Sustained chemogenetic activation of locus coeruleus norepinephrine neurons promotes dopaminergic neuron survival in synucleinopathy.

Authors:  Predrag Jovanovic; Yidan Wang; Jean-Philippe Vit; Edward Novinbakht; Nancy Morones; Elliot Hogg; Michele Tagliati; Celine E Riera
Journal:  PLoS One       Date:  2022-03-22       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.